Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches - Giuseppe Privitera, Daniela Pugliese, Loris Riccardo Lopetuso, Franco Scaldaferri, Matteo Neri, Luisa Guidi, Antonio Gasbarrini, Alessandro Armuzzi, 2021
Is miR-223 Upregulation in Inflammatory Bowel Diseases a Protective Response ?
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Biomimetic MOF Nanoparticles Delivery of C-Dot Nanozyme and CRISPR/Cas9 System for Site-Specific Treatment of Ulcerative Colitis
Florian Rieder, MD, on Biologic Agents in IBD Management
Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers - eBioMedicine
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives - The Lancet Gastroenterology & Hepatology
TNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability - Mucosal Immunology
Digestive Diseases News - Medical Professionals - Mayo Clinic
Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach - Hedin - 2021 - Journal of Internal Medicine - Wiley Online Library
Predicting diagnostic biomarkers associated with immune infiltration in Crohn's disease based on machine learning and bioinformatics, European Journal of Medical Research
(PDF) Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations
Digestive Diseases News - Medical Professionals - Mayo Clinic